Hyperlab Solution Spółka z Ograniczoną Odpowiedzialnością (KRS 0000742820, NIP 6772436775) is a Polish company, headquartered in Kraków, Małopolskie voivodeship. HYPERLAB SOLUTION operates in: Other research and experimental development on natural sciences and engineering (PKD 72.19.Z). Industry: Research and development. The company has been listed in the National Court Register since August 2, 2018. HYPERLAB SOLUTION's most recently reported net revenue was 139.4 K PLN for 2024.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - Hyperlab Solution
Identity
- Name
- Hyperlab Solution Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- August 2, 2018
- Registry status as of
- January 20, 2026
- Latest entry
- January 19, 2026
- Founding act
- 19.06.2018R., NOTARIUSZ KATARZYNA JANICKA, KANCELARIA NOTARIALNA NOTARIUSZE WARCZAK-MAŃDZIAK & JANICKA SPÓŁKA PARTNERSKA…
Articles of association history (1)
- June 19, 2018: 19.06.2018R., NOTARIUSZ KATARZYNA JANICKA, KANCELARIA NOTARIALNA NOTARIUSZE WARCZAK-MAŃDZIAK & JANICKA SPÓŁKA PARTNERSKA WE WROCŁAWIU, REPERTORIUM A NUMER 8373/2018
Activities
Main activity
72.19.ZOther research and experimental development on natural sciences and engineering
Other activities
Address and contact
- Address
- UL. CZARNOWIEJSKA, 36, 30-054, KRAKÓW, POLSKA
- Voivodeship
- MAŁOPOLSKIE
- District
- KRAKÓW
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- AE:PL-36955-29157-SSUJF-26
Risk and payment profile - Hyperlab Solution
Credibility rating
75.1 / 100
Good credibility
Insolvency risk
Very low
Low threat
Closure risk
1
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
0
0/8 yrs
Board changes
0
0/8 yrs
PKD changes
0
0/8 yrs
Name changes
0
0/8 yrs
Data from 8 years of registry activity.
Credibility history
Payment reliability score from 2018–2024
Current: B (75/100)
Trend: improving (+3.8 pts/year)
High payment credibility - the company's financial condition is good and the risk of cooperating with it is low.
Trade credit limit history
Standard limit from 2018–2024
Current: 134.0 K PLN
Safe: 87.1 K PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - Hyperlab Solution
Founded
August 2, 2018
7 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
KRAKÓW
MAŁOPOLSKIE
Primary PKD
72.19.Z
Other research and experimental development on natural sciences and…
Share capital
10.0 K PLN
181 shares total
Shareholders
2
shareholders
Board
1 person
Proxies: 1
Filed years
7 years
2018–2024 · profitable: 6/7
Registry entries
24
latest: January 19, 2026
Revenue
139.4 K PLN
2024
Net profit
94.3 K PLN
2024
Assets
1.1 M PLN
2024
Equity
491.9 K PLN
2024
EBITDA
103.7 K PLN
2024
Valuation
733.1 K PLN
Low confidence
Low confidence
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Hyperlab Solution.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.
News
Captor Therapeutics: PLN 36 m of cash at 30 September 2025, runway to mid-2026 - clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
